Updated australian guidelines for mild asthma: What’s changed and why?

Helen K. Reddel

doi:10.18773/austprescr.2020.076

Updated australian guidelines for mild asthma: What’s changed and why?

Helen K. Reddel^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

5 Citations (Scopus)

22 Downloads (Pure)

Abstract

The Australian asthma guidelines have recently been updated and include additional treatment options for adults and adolescents with mild asthma. Mild asthma is not necessarily a benign condition and patients are still at risk of severe flare-ups, particularly if they overuse short-acting beta₂ agonists such as a salbutamol inhaler. For adults and adolescents with mild asthma, the updated guidelines include as-needed inhaled low-dose budesonide–formoterol as an alternative to daily low-dose inhaled corticosteroid plus as-needed short-acting beta₂ agonist. The budesonide–formoterol combination should be taken as needed to provide symptom relief and reduce the risk of severe exacerbations.

Original language	English
Pages (from-to)	220-224
Number of pages	5
Journal	Australian Prescriber
Volume	43
Issue number	6
DOIs	https://doi.org/10.18773/austprescr.2020.076
Publication status	Published - Dec 2020
Externally published	Yes

Bibliographical note

Copyright 2020 NPS MedicineWise 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

Asthma
Budesonide– formoterol
Corticosteroids

Access to Document

10.18773/austprescr.2020.076Licence: CC BY-NC-ND

Publisher version (open access)Final published version, 222 KBLicence: CC BY-NC-ND

Cite this

@article{95b13ab90d6e495daf28619878ab4ed0,

title = "Updated australian guidelines for mild asthma: What{\textquoteright}s changed and why?",

abstract = "The Australian asthma guidelines have recently been updated and include additional treatment options for adults and adolescents with mild asthma. Mild asthma is not necessarily a benign condition and patients are still at risk of severe flare-ups, particularly if they overuse short-acting beta2 agonists such as a salbutamol inhaler. For adults and adolescents with mild asthma, the updated guidelines include as-needed inhaled low-dose budesonide–formoterol as an alternative to daily low-dose inhaled corticosteroid plus as-needed short-acting beta2 agonist. The budesonide–formoterol combination should be taken as needed to provide symptom relief and reduce the risk of severe exacerbations.",

keywords = "Asthma, Budesonide– formoterol, Corticosteroids",

author = "Reddel, \{Helen K.\}",

note = "Copyright 2020 NPS MedicineWise 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2020",

month = dec,

doi = "10.18773/austprescr.2020.076",

language = "English",

volume = "43",

pages = "220--224",

journal = "Australian Prescriber",

issn = "0312-8008",

publisher = "Therapeutic Guidelines Ltd",

number = "6",

}

TY - JOUR

T1 - Updated australian guidelines for mild asthma

T2 - What’s changed and why?

AU - Reddel, Helen K.

N1 - Copyright 2020 NPS MedicineWise 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2020/12

Y1 - 2020/12

N2 - The Australian asthma guidelines have recently been updated and include additional treatment options for adults and adolescents with mild asthma. Mild asthma is not necessarily a benign condition and patients are still at risk of severe flare-ups, particularly if they overuse short-acting beta2 agonists such as a salbutamol inhaler. For adults and adolescents with mild asthma, the updated guidelines include as-needed inhaled low-dose budesonide–formoterol as an alternative to daily low-dose inhaled corticosteroid plus as-needed short-acting beta2 agonist. The budesonide–formoterol combination should be taken as needed to provide symptom relief and reduce the risk of severe exacerbations.

AB - The Australian asthma guidelines have recently been updated and include additional treatment options for adults and adolescents with mild asthma. Mild asthma is not necessarily a benign condition and patients are still at risk of severe flare-ups, particularly if they overuse short-acting beta2 agonists such as a salbutamol inhaler. For adults and adolescents with mild asthma, the updated guidelines include as-needed inhaled low-dose budesonide–formoterol as an alternative to daily low-dose inhaled corticosteroid plus as-needed short-acting beta2 agonist. The budesonide–formoterol combination should be taken as needed to provide symptom relief and reduce the risk of severe exacerbations.

KW - Asthma

KW - Budesonide– formoterol

KW - Corticosteroids

UR - https://www.scopus.com/pages/publications/85097374396

U2 - 10.18773/austprescr.2020.076

DO - 10.18773/austprescr.2020.076

M3 - Review article

C2 - 33363311

AN - SCOPUS:85097374396

SN - 0312-8008

VL - 43

SP - 220

EP - 224

JO - Australian Prescriber

JF - Australian Prescriber

IS - 6

ER -

Updated australian guidelines for mild asthma: What’s changed and why?

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this